STOCK TITAN

MeiraGTx Holdings (NASDAQ: MGTX) CFO sells 56,000 shares in plan trade

(Very High)
(Negative)
Form Type
4

Rhea-AI Filing Summary

MeiraGTx Holdings plc CFO & COO Richard Giroux sold 56,000 Ordinary Shares on July 21, 2026 at a $12.51 weighted average price, with individual trades executed between $12.00 and $12.63 per share. The reported price is a weighted average, reflecting multiple sale transactions.

The sales were effected under a Rule 10b5-1 trading plan adopted on November 18, 2025. Following these transactions, Giroux is reported as directly holding 908,530 Ordinary Shares, with additional indirect holdings of 5,152 shares by his spouse and 85,000 shares by Aigle Healthcare Partners III LLC.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Giroux Richard
Role CFO & COO
Sold 56,000 shs ($701K)
Type Security Shares Price Value
Sale Ordinary Shares F1, F2, F3 56,000 $12.51 $701K
holding Ordinary Shares -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: Ordinary Shares — 908,530 shares (Direct); Ordinary Shares — 5,152 shares (Indirect, By Spouse); Ordinary Shares — 85,000 shares (Indirect, By Aigle Healthcare Partners III LLC)
Footnotes (3)
  1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.63, inclusive.
  3. F3. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
Shares sold 56,000 shares Ordinary Shares sold on July 21, 2026
Weighted average sale price $12.51 per share Weighted average price across multiple sale transactions
Sale price range $12.00–$12.63 per share Range of prices for the multiple sale transactions
Direct holdings after sale 908,530 shares Directly held Ordinary Shares following the transactions
Indirect holdings via spouse 5,152 shares Ordinary Shares indirectly held by spouse
Indirect holdings via Aigle Healthcare Partners III LLC 85,000 shares Ordinary Shares indirectly held by Aigle Healthcare Partners III LLC
Rule 10b5-1 plan adoption date November 18, 2025 Date the Rule 10b5-1 trading plan was adopted
Rule 10b5-1 trading plan regulatory
"The sales were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sales price financial
"The price reported reflects the weighted average sales price"
Ordinary Shares financial
"Security title reported as Ordinary Shares in the transactions table"
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider share sale did MeiraGTx (MGTX) report for Richard Giroux?

MeiraGTx reported that CFO & COO Richard Giroux sold 56,000 Ordinary Shares on July 21, 2026. The sale was executed in multiple transactions and disclosed with detailed pricing information and remaining holdings.

How many MeiraGTx (MGTX) shares did the CFO sell and at what prices?

Richard Giroux sold 56,000 Ordinary Shares at a weighted average price of $12.51 per share. The trades occurred in multiple transactions at prices ranging from $12.00 to $12.63, inclusive, according to the disclosure.

Was the MeiraGTx (MGTX) CFO share sale made under a Rule 10b5-1 plan?

Yes. The sales were effected under a Rule 10b5-1 trading plan adopted by Richard Giroux on November 18, 2025. This indicates the transactions followed a pre-established trading schedule rather than discretionary timing.

How many MeiraGTx (MGTX) shares does Richard Giroux hold after the reported sale?

After the sale, Richard Giroux is reported as directly holding 908,530 Ordinary Shares of MeiraGTx. The disclosure also notes additional indirect shareholdings through his spouse and an affiliated LLC.

What indirect MeiraGTx (MGTX) shareholdings are reported for Richard Giroux?

In addition to direct holdings, the disclosure lists 5,152 Ordinary Shares indirectly held by his spouse and 85,000 Ordinary Shares indirectly held by Aigle Healthcare Partners III LLC, both attributed as indirect ownership interests.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Giroux Richard

(Last)(First)(Middle)
655 THIRD AVENUE
SUITE 1115

(Street)
NEW YORK NEW YORK 10017

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
MeiraGTx Holdings plc [ MGTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CFO & COO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares07/21/2026S(1)56,000D$12.51(2)(3)908,530D
Ordinary Shares5,152IBy Spouse
Ordinary Shares85,000IBy Aigle Healthcare Partners III LLC
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
2. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.63, inclusive.
3. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
/s/ Richard Giroux07/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)